Arvinas, Inc. announced that it will present new preclinical data on its investigational oral PROTAC BCL6 degrader, ARV-393, at the upcoming European Hematology Association (EHA) meeting in Milan from ...
Arvinas, Inc., a biotechnology company focused on targeted protein degradation therapies, announced that new preclinical data for its investigational drug ARV-393 will be presented at the upcoming ...
– Company to showcase preclinical studies of ARV-393, an investigational oral PROTAC BCL6 degrader, as a single agent in models of nodal T-follicular helper cell lymphoma, angioimmunoblastic-type ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback